AndHealth operates virtual Centers of Excellence that deliver root-cause, disease-reversal programs, beginning with a Migraine Reversal VCOE and soon launching VCOEs for autoimmune conditions including rheumatoid arthritis, psoriasis, ulcerative colitis and Crohn’s. The company offers its programs as an employer-sponsored benefit, working with self-funded employers and benefits brokers and aligning interests around outcomes and guaranteed patient participation. Leadership includes CEO Matt Scantland and team members from CoverMyMeds, clinical leaders such as Dr. Robert Sheeler, and national virtual practice Medical Director Dr. Robert Darling. AndHealth emphasizes precision behavioral design and system-biology approaches to drive high patient engagement and address comorbid chronic conditions. A University of Maryland study of the Migraine Reversal Program found 60% of severe/chronic participants no longer met ICHD-3 diagnostic criteria after the program, and anecdotal results include an 80% reduction in attacks for a long‑suffering patient. The company highlights a large addressable population—roughly 30 million working-age people affected by these conditions—and positions its model to reduce employer costs, unlock productivity, and advance DEI objectives. AndHealth states it partners with employers, health plans, public entities and individuals to scale its virtual disease-reversal care model.

Total raised

$57M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2022